Corbus Pharmaceuticals Holdings Inc. (CRBP) Coverage Initiated by Analysts at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a report released on Tuesday morning. The brokerage issued a buy rating and a $17.00 price objective on the biopharmaceutical company’s stock.
Separately, Aegis set a $12.00 price target on Corbus Pharmaceuticals Holdings and gave the stock a buy rating in a research note on Monday, September 19th.
Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded up 18.38% during midday trading on Tuesday, hitting $8.31. The stock had a trading volume of 2,440,627 shares. The stock’s market cap is $363.55 million. Corbus Pharmaceuticals Holdings has a 12-month low of $1.01 and a 12-month high of $8.40. The stock has a 50-day moving average price of $5.38 and a 200-day moving average price of $3.34.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 890.44%. Equities analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.40) earnings per share for the current year.
In related news, CFO Sean F. Moran bought 30,800 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Thursday, September 8th. The shares were purchased at an average price of $5.12 per share, with a total value of $157,696.00. Following the purchase, the chief financial officer now owns 330,110 shares in the company, valued at $1,690,163.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sean F. Moran bought 17,900 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, August 26th. The stock was bought at an average cost of $3.92 per share, for a total transaction of $70,168.00. Following the purchase, the chief financial officer now owns 299,310 shares in the company, valued at approximately $1,173,295.20. The disclosure for this purchase can be found here. 11.60% of the stock is owned by corporate insiders.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.